Paragraph

TherapeuticsMD Announces First Quarter 2022 Financial Results

Retrieved on: 
Monday, May 16, 2022 - 9:05pm

Please connect to the website prior to the start of the presentation to ensure adequate time for any software downloads that may be necessary to listen to the webcast.

Key Points: 
  • Please connect to the website prior to the start of the presentation to ensure adequate time for any software downloads that may be necessary to listen to the webcast.
  • A replay of the webcast will be archived on the website for at least 30 days.
  • Please see the Full Prescribing Information, including indication and Boxed WARNING, for each TherapeuticsMD product as follows:
    This press release by TherapeuticsMD, Inc. may contain forward-looking statements.
  • Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties, many of which are outside of the companys control.

REPLY: The Board of Directors Approves the Quarterly Report Dated 31 March 2022

Retrieved on: 
Friday, May 13, 2022 - 12:24pm

Today, the Board of Directors of Reply S.p.A. [EXM, STAR: REY] approved the results as at 31 March 2022.

Key Points: 
  • Today, the Board of Directors of Reply S.p.A. [EXM, STAR: REY] approved the results as at 31 March 2022.
  • In the first quarter of 2022 the consolidated EBITDA was 70.9 million compared to 59.6 million in 2021, equal to 16.1% of the turnover.
  • EBIT, from January to March, was 57.7 million (47.9 million in 2021), and is equal to 13.1% of the turnover.
  • The net financial position of the Group on 31 March 2022 is also positive by 279.7 million.

DGAP-News: Reply SpA: The Board of Directors approves the quarterly report dated 31 March 2022

Retrieved on: 
Friday, May 13, 2022 - 12:08pm

All economic and financial indicators grew:

Key Points: 
  • All economic and financial indicators grew:
    Today, the Board of Directors of Reply S.p.A. [EXM, STAR: REY] approved the results as at 31 March 2022.
  • In the first quarter of 2022 the consolidated EBITDA was 70.9 million compared to 59.6 million in 2021, equal to 16.1% of the turnover.
  • EBIT, from January to March, was 57.7 million (47.9 million in 2021), and is equal to 13.1% of the turnover.
  • The net financial position of the Group on 31 March 2022 is also positive by 279.7 million.

Eton Pharmaceuticals Reports First Quarter 2022 Financial Results

Retrieved on: 
Thursday, May 12, 2022 - 9:02pm

DEER PARK, Ill., May 12, 2022 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today reported financial results for the first quarter ended March 31, 2022.

Key Points: 
  • DEER PARK, Ill., May 12, 2022 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today reported financial results for the first quarter ended March 31, 2022.
  • For the first quarter of 2022, Eton reported revenue of $2.2 million from product sales and royalties, representing a 100% increase from the fourth quarter of 2021.
  • Eton reported no licensing revenue in the first quarter of 2022, compared with $11.5 million in the prior year period.
  • Eton reported diluted earnings per share (EPS) of ($0.21) in the first quarter of 2022, compared with $0.19 in the first quarter of 2021.

TherapeuticsMD to Report First Quarter 2022 Financial Results on May 16, 2022

Retrieved on: 
Tuesday, May 10, 2022 - 9:05pm

A replay of the webcast will be archived on the website for at least 30 days.

Key Points: 
  • A replay of the webcast will be archived on the website for at least 30 days.
  • TherapeuticsMD, Inc. is an innovative, leading healthcare company, focused on developing and commercializing novel products exclusively for women.
  • TherapeuticsMD is committed to advancing the health of women and championing awareness of their healthcare issues.
  • To learn more about TherapeuticsMD, please visit therapeuticsmd.com or follow us on Twitter: @TherapeuticsMD and on Facebook: TherapeuticsMD.

Resolutions of the General Shareholders Meeting of INVL Baltic Farmland

Retrieved on: 
Wednesday, April 27, 2022 - 7:38am

Until the day of the General Shareholders Meeting the reserve for the purchase of own shares which is equal to EUR 3,079,669 not used.

Key Points: 
  • Until the day of the General Shareholders Meeting the reserve for the purchase of own shares which is equal to EUR 3,079,669 not used.
  • (iii) The period during which the public joint-stock company INVL Baltic Farmland may purchase its own shares 18 months from the day of this resolution.
  • From the date of this resolution, the resolution of the General Shareholders Meeting on 9 April 2021 on the acquisition of own shares expires.
  • Regarding the dividend payment for the shareholders and ex-date:
    Persons, who will be shareholders of INVL Baltic Farmland at the end of 11 May 2022 the tenth day after the General Shareholders Meeting to approve the resolution to allocate part of Companys profit for the payment of dividends, are entitled to receive dividends.

Renesas Announces Acquisition of and Tender Offer for Own Shares

Retrieved on: 
Wednesday, April 27, 2022 - 7:23am

Renesas also determined that, by acquiring its own shares in accordance with the statutory procedures for tender offers, a tender offer would also ensure the transparency of the transaction.

Key Points: 
  • Renesas also determined that, by acquiring its own shares in accordance with the statutory procedures for tender offers, a tender offer would also ensure the transparency of the transaction.
  • As stated below, Renesas believes that, when calculating the purchase price per share in the Tender Offer (the "Tender Offer Price"), priority should be given to the market value of the shares of Renesas common stock.
  • In addition, on April 27, 2022, Renesas entered into a tender agreement with INCJ (the Tender Agreement) in which INCJ agreed to tender 168,067,175 shares (ownership ratio: 8.65%; the INCJ Tendered Shares), a part of the shares of Renesas common stock owned by INCJ, through the Tender Offer.
  • issued by Renesas is commenced by the end of the Tender Offer Period by a third party other than Renesas (the "Competitive Tender Offer"), and if, with respect to all or part of INCJ Tendered Shares, INCJs non-tendering of shares in the Competitive Tender Offer and non-termination of the contracts relating to the Tender Offer constitutes, or is objectively and reasonably determined to constitute, a breach of the duty of due care of a good manager as a director of INCJ, INCJ shall be entitled to terminate the contracts relating to the Tender Offer and tender all or part of the INCJ Tendered Shares in the Competitive Tender Offer on the condition that INCJ pays a penalty to Renesas.

REPLY S.p.A.: Shareholders’ Meeting Approves the 2021 Financial Statements:

Retrieved on: 
Friday, April 22, 2022 - 11:15am

The General Shareholders meeting of Reply S.p.A. [MTA, STAR: REY] today approved the Financial Statements for the financial year 2021, confirming the distribution of a gross dividend of 0.80 per share.

Key Points: 
  • The General Shareholders meeting of Reply S.p.A. [MTA, STAR: REY] today approved the Financial Statements for the financial year 2021, confirming the distribution of a gross dividend of 0.80 per share.
  • The Reply Group closed the 2021 financial year with a consolidated turnover of 1,483.8 million, recording a 18.7% increase compared to 1,250.2 million for the 2020 financial year.
  • The Shareholders' Meeting also approved Section II of the Remuneration Report drafted pursuant to Article 123-ter of Legislative Decree 58/1998.
  • Reply services include: Consulting, System Integration and Digital Services www.reply.com
    This press release is a translation, the Italian version will prevail.

TherapeuticsMD Completes the Divestiture of vitaCare Prescription Services to GoodRx in a Cash Transaction Valued at $150 Million

Retrieved on: 
Thursday, April 14, 2022 - 9:15pm

TherapeuticsMD, Inc. (NASDAQ: TXMD), (TXMD or the Company) an innovative, leading womens healthcare company, announced today the closing of the divestiture of vitaCare Prescription Services to GoodRx (NASDAQ: GDRX), in a cash transaction valued at $150 million, subject to a working capital adjustment.

Key Points: 
  • TherapeuticsMD, Inc. (NASDAQ: TXMD), (TXMD or the Company) an innovative, leading womens healthcare company, announced today the closing of the divestiture of vitaCare Prescription Services to GoodRx (NASDAQ: GDRX), in a cash transaction valued at $150 million, subject to a working capital adjustment.
  • TherapeuticsMD remains eligible to receive an additional $7 million in cash consideration contingent on vitaCares financial performance through 2023.
  • We are pleased to complete the sale of vitaCare Prescription Services.
  • To learn more about TherapeuticsMD, please visit therapeuticsmd.com or follow us on Twitter: @TherapeuticsMD and on Facebook: TherapeuticsMD.

Press Release: EUROAPI listing on Euronext Paris expected on May 6, 2022

Retrieved on: 
Friday, April 1, 2022 - 6:30am

Sanofi announced today that the French Autorit des marchs financiers (AMF) has approved the listing prospectus prepared by EUROAPI in connection with the intended listing of its shares on the regulated market of Euronext Paris.

Key Points: 
  • Sanofi announced today that the French Autorit des marchs financiers (AMF) has approved the listing prospectus prepared by EUROAPI in connection with the intended listing of its shares on the regulated market of Euronext Paris.
  • Main features of the Distribution are as follows:
    The Distribution ratio will be one (1) EUROAPI share per twenty three (23) Sanofi shares.
  • EUROAPI draws attention to the risk factors contained in Chapter 3 and Section 22.2 of the listing prospectus.
  • This press release constitutes an advertisement for the purposes of the Prospectus Regulation relating to the intention of EUROAPI to proceed with its proposed listing on the regulated market of Euronext Paris (the Admission).